Zolbetuximab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | CLDN18.2 |
Clinical data | |
Other names | IMAB362; Claudiximab |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII | |
![]() ![]() |
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]
The drug is in phase II clinical trials as of January 2013.[2]
Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer (and a phase III trial will be planned).[3]
References[]
- ^ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de.
- ^ "Search of: IMAB362 - List Results - ClinicalTrials.gov". clinicaltrials.gov.
- ^ "Antibody Shines in Advanced Gastric Cancer". medpagetoday.com. 5 June 2016.
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Experimental drugs
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs